An increasing body of evidence suggests that the long-acting muscarinic antagonist (LAMA)/long-acting β2-agonist (LABA) combination appears to play an important role in maximizing bronchodilation, with studies to date indicating that combining different classes of bronchodilators may result in significantly greater improvements in lung function compared to the use of a single drug, and that these combinations are well tolerated in patients with moderate-to-severe chronic obstructive pulmonary disease (COPD). An inhaled, fixed-dose combination of two 24-hour bronchodilators, the LAMA umeclidinium and the LABA vilanterol, is under development as a once-daily treatment for COPD. The efficacy of both mono-components has already been demonstrated. The information currently available suggests that umeclidinium/vilanterol is an effective once-daily dual bronchodilator fixed-dose combination in the treatment of COPD. However, it remains to be seen if it compares favorably with current therapies. Moreover, the question remains whether umeclidinium/vilanterol fixed-dose combination, which significantly improves FEV1, is also associated with improvements in other outcome measures that are important to COPD patients.

Cazzola, M., Segreti, A., Matera, M. (2013). New developments in the combination treatment of COPD: focus on umeclidinium/vilanterol. DRUG DESIGN, DEVELOPMENT AND THERAPY, 7, 1201-1208 [10.2147/DDDT.S39449].

New developments in the combination treatment of COPD: focus on umeclidinium/vilanterol

CAZZOLA, MARIO;SEGRETI, ANDREA;
2013-01-01

Abstract

An increasing body of evidence suggests that the long-acting muscarinic antagonist (LAMA)/long-acting β2-agonist (LABA) combination appears to play an important role in maximizing bronchodilation, with studies to date indicating that combining different classes of bronchodilators may result in significantly greater improvements in lung function compared to the use of a single drug, and that these combinations are well tolerated in patients with moderate-to-severe chronic obstructive pulmonary disease (COPD). An inhaled, fixed-dose combination of two 24-hour bronchodilators, the LAMA umeclidinium and the LABA vilanterol, is under development as a once-daily treatment for COPD. The efficacy of both mono-components has already been demonstrated. The information currently available suggests that umeclidinium/vilanterol is an effective once-daily dual bronchodilator fixed-dose combination in the treatment of COPD. However, it remains to be seen if it compares favorably with current therapies. Moreover, the question remains whether umeclidinium/vilanterol fixed-dose combination, which significantly improves FEV1, is also associated with improvements in other outcome measures that are important to COPD patients.
2013
Pubblicato
Rilevanza internazionale
Articolo
Esperti anonimi
Settore MED/10 - MALATTIE DELL'APPARATO RESPIRATORIO
English
Adrenergic beta-2 Receptor Agonists; Humans; Outcome Assessment (Health Care); dual bronchodilation; Forced Expiratory Volume; Drug Combinations; Chlorobenzenes; Muscarinic Antagonists; Quinuclidines; Delayed-Action Preparations; muscarinic antagonist; Benzyl Alcohols; Administration, Inhalation; Bronchodilator Agents; Pulmonary Disease, Chronic Obstructive; COPD
Cazzola, M., Segreti, A., Matera, M. (2013). New developments in the combination treatment of COPD: focus on umeclidinium/vilanterol. DRUG DESIGN, DEVELOPMENT AND THERAPY, 7, 1201-1208 [10.2147/DDDT.S39449].
Cazzola, M; Segreti, A; Matera, M
Articolo su rivista
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2108/90083
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 36
  • ???jsp.display-item.citation.isi??? 33
social impact